Hims & Hers Health (NYSE:HIMS) Stock Price Down 2% on Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s share price was down 2% on Tuesday following insider selling activity. The stock traded as low as $60.70 and last traded at $61.10. Approximately 10,278,372 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 19,431,837 shares. The stock had previously closed at $62.34.

Specifically, CEO Andrew Dudum sold 47,534 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $58.25, for a total transaction of $2,768,855.50. Following the transaction, the chief executive officer now owns 285,194 shares in the company, valued at $16,612,550.50. The trade was a 14.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $58.40, for a total transaction of $7,482,616.80. Following the transaction, the chief executive officer now owns 89,311 shares in the company, valued at $5,215,762.40. The trade was a 58.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. In related news, CFO Oluyemi Okupe sold 11,581 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $60.22, for a total transaction of $697,407.82. Following the completion of the transaction, the chief financial officer now owns 113,816 shares in the company, valued at $6,853,999.52. The trade was a 9.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Analysts Set New Price Targets

A number of research firms have commented on HIMS. UBS Group reissued a "mixed" rating on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley cut their price objective on shares of Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 29th. Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Leerink Partners lifted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Finally, TD Cowen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a report on Tuesday, April 29th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $37.67.

Hims & Hers Health Stock Performance

The firm has a market capitalization of $13.68 billion, a PE ratio of 138.87 and a beta of 1.84. The firm's 50 day moving average price is $36.01 and its 200-day moving average price is $34.19.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The company had revenue of $586.01 million for the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.05 earnings per share. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently modified their holdings of the stock. Crewe Advisors LLC purchased a new position in Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. raised its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 1,100 shares during the last quarter. Blume Capital Management Inc. lifted its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth $38,000. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.